The published bio-medical journal literature about the efficacy of Coenzyme Q10 adjunct treatment in breast cancer care is sparse but promising. So concludes the author of a 2017 systematic review of the journal articles indexed in PubMed. PubMed is the free public index to the National Library of Medicine’s Medline database [Tafazoli].
More well-designed clinical studies are needed to provide answers to questions about the adjuvant use of Coenzyme Q10 in breast cancer treatment and care:
- Is Coenzyme Q10 effective as a single intervention agent?
- Is Coenzyme Q10 more effective in combination with other nutritional supplements such as essential fatty acids and selenium?
- What formulations and what daily dosages of Coenzyme Q10 are most effective?
Documentation about Coenzyme Q10 and breast cancer care
Coenzyme Q10 concentrations and breast cancer
- Evidence from human breast tissue samples shows that Coenzyme Q10 concentrations are much lower in cancerous tissue than in normal tissue [Tafazoli].
- Data from a case-control study has shown an inverse relationship between plasma Coenzyme Q10 concentrations and the incidence of breast cancer, independent of menopausal status [Tafazoli].
- Cell line studies have shown that the addition of Coenzyme Q10 does not inhibit the apoptotic, anti-growth, and anti-colonization effects of the chemotherapy drug doxorubicin – trade name Adriamycin while it does protect the heart muscle [Tafazoli].
- Coenzyme Q10 supplementation added to chemotherapy with doxorubicin (Adriamycin) prevents the mitochondrial damage and subsequent cardio-toxicity caused by reactive oxygen species produced during the treatment with doxorubicin [Tafazoli].
Coenzyme Q10 and mammary carcinomas
An animal study has shown that oral administration of Coenzyme Q10 had the following effects on rats with induced mammary carcinomas [Tafazoli]: